Skip to content

Karen L. Cropsey

3 papers in the library · 183 citations · publishing 2014-2026

Papers

The relationships of classic psychedelic use with criminal behavior in the United States adult population

Journal of Psychopharmacology October 17, 2017 Peter S. Hendricks, Michael Crawford, Karen L. Cropsey et al. 91 citations

Lifetime use of classic psychedelics, including psilocybin, is associated with lower odds of recent larceny/theft, assault, and arrests for property or violent crimes among over 480,000 U.S. adults surveyed from 2002 to 2014. In contrast, illicit use of other drugs generally increased the odds of these criminal behaviors. Lifetime classic psychedelic use was linked to higher odds of drug distribution, similar to other substances. The findings suggest a potential protective effect of psilocybin against antisocial criminal behavior and support further clinical research in forensic settings.

Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision

Journal of Psychopharmacology January 1, 2014 Peter S. Hendricks, Christopher Clark, Matthew W. Johnson et al. 88 citations

Hallucinogen use among individuals under community corrections supervision with a history of substance involvement was associated with a reduced likelihood of supervision failure, such as noncompliance with legal requirements including alcohol and other drug use. In a longitudinal study of 25,622 people, those who used hallucinogens had 40% lower odds of supervision failure after controlling for confounding factors. The findings suggest hallucinogens may promote abstinence and prosocial behavior in a population with high rates of recidivism.

Psilocybin in the Treatment of Cocaine Use Disorder

JAMA Network Open May 7, 2026 Peter S. Hendricks, Sara Lappan, Richard C. Shelton et al. 4 citations

A single 25 mg dose of psilocybin, combined with psychotherapy, led to a higher percentage of cocaine-abstinent days, a greater likelihood of complete abstinence, and a longer time before the first cocaine lapse over 180 days compared with an active placebo (100 mg diphenhydramine) in a randomized, quadruple-blind trial. Among 40 participants with cocaine use disorder, 33 were men, 33 were Black, and most had low income. Psilocybin appeared safe, with no serious adverse events, and may offer a treatment for cocaine use disorder in underrepresented populations.